QLS1303 / Qilu Pharma - LARVOL DELTA

Discovery of QLS1303, a potent and selective KIF18A inhibitor with robust anti-tumor activity in CIN+ preclinical cancer models (AACR 2026) - "This synthetic-lethal interaction makes KIF18A as an attractive, cancer-selective therapeutic target, which prompted multiple drug-discovery programs, including AMG 650, a clinical-stage KIF18A inhibitor. QLS1303 is a highly potent, selective, and orally bioavailable KIF18A inhibitor, demonstrating robust anti-tumor activity in CIN+ preclinical models and a compelling safety profile. These data strongly support its advancement into clinical studies."

Preclinical • Oncology • Solid Tumor • KIF18A